Free Trial
→ A new income category is drawing serious money - here's why (From Investors Alley) (Ad)tc pixel Free IMAC Stock Alerts

IMAC (IMAC) Competitors

IMAC logo
$0.0006 0.00 (0.00%)
As of 10/15/2026
Compare

IMAC vs. NVOS, BACK, AONCW, BTSGU, and LFMDP

Should you buy IMAC stock or one of its competitors? IMAC's main competitors and comparable companies include Novo Integrated Sciences (NVOS), IMAC (BACK), American Oncology Network (AONCW), BrightSpring Health Services (BTSGU), and LifeMD (LFMDP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare providers & services" industry.

How does IMAC compare to Novo Integrated Sciences?

IMAC (NASDAQ:IMAC) and Novo Integrated Sciences (NASDAQ:NVOS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

IMAC has higher revenue and earnings than Novo Integrated Sciences. Novo Integrated Sciences is trading at a lower price-to-earnings ratio than IMAC, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$15.22M0.00-$10.54M-$0.27N/A
Novo Integrated Sciences$13.52M0.00-$16.17M-$0.87N/A

IMAC has a beta of -0.88, suggesting that its stock price is 188% less volatile than the broader market. Comparatively, Novo Integrated Sciences has a beta of 5.83, suggesting that its stock price is 483% more volatile than the broader market.

24.3% of IMAC shares are owned by institutional investors. Comparatively, 5.7% of Novo Integrated Sciences shares are owned by institutional investors. 10.0% of IMAC shares are owned by insiders. Comparatively, 10.4% of Novo Integrated Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

IMAC has a net margin of -75.40% compared to Novo Integrated Sciences' net margin of -121.55%. IMAC's return on equity of -52.17% beat Novo Integrated Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
IMAC-75.40% -52.17% -34.51%
Novo Integrated Sciences -121.55%-93.07%-46.28%

In the previous week, IMAC had 4 more articles in the media than Novo Integrated Sciences. MarketBeat recorded 4 mentions for IMAC and 0 mentions for Novo Integrated Sciences. IMAC's average media sentiment score of 0.05 beat Novo Integrated Sciences' score of 0.00 indicating that IMAC is being referred to more favorably in the media.

Company Overall Sentiment
IMAC Neutral
Novo Integrated Sciences Neutral

Summary

IMAC beats Novo Integrated Sciences on 10 of the 13 factors compared between the two stocks.

How does IMAC compare to IMAC?

IMAC (NASDAQ:BACK) and IMAC (NASDAQ:IMAC) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

5.8% of IMAC shares are owned by institutional investors. Comparatively, 24.3% of IMAC shares are owned by institutional investors. 12.3% of IMAC shares are owned by company insiders. Comparatively, 10.0% of IMAC shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

IMAC has a beta of 2, indicating that its share price is 100% more volatile than the broader market. Comparatively, IMAC has a beta of -0.88, indicating that its share price is 188% less volatile than the broader market.

In the previous week, IMAC had 4 more articles in the media than IMAC. MarketBeat recorded 4 mentions for IMAC and 0 mentions for IMAC. IMAC's average media sentiment score of 0.05 beat IMAC's score of 0.00 indicating that IMAC is being referred to more favorably in the news media.

Company Overall Sentiment
IMAC Neutral
IMAC Neutral

IMAC has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of 0.00% beat IMAC's return on equity.

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -325.44%
IMAC -75.40%-52.17%-34.51%

IMAC has higher earnings, but lower revenue than IMAC. IMAC is trading at a lower price-to-earnings ratio than IMAC, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$72.05K0.01-$9.42M-$3.12N/A
IMAC$15.22M0.00-$10.54M-$0.27N/A

Summary

IMAC beats IMAC on 7 of the 13 factors compared between the two stocks.

How does IMAC compare to American Oncology Network?

IMAC (NASDAQ:IMAC) and American Oncology Network (NASDAQ:AONCW) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

American Oncology Network has a net margin of 0.00% compared to IMAC's net margin of -75.40%. American Oncology Network's return on equity of 0.00% beat IMAC's return on equity.

Company Net Margins Return on Equity Return on Assets
IMAC-75.40% -52.17% -34.51%
American Oncology Network N/A N/A N/A

American Oncology Network has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$15.22M0.00-$10.54M-$0.27N/A
American Oncology Network$1.34BN/AN/AN/AN/A

24.3% of IMAC shares are owned by institutional investors. 10.0% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, IMAC had 4 more articles in the media than American Oncology Network. MarketBeat recorded 4 mentions for IMAC and 0 mentions for American Oncology Network. IMAC's average media sentiment score of 0.05 beat American Oncology Network's score of 0.00 indicating that IMAC is being referred to more favorably in the media.

Company Overall Sentiment
IMAC Neutral
American Oncology Network Neutral

Summary

IMAC and American Oncology Network tied by winning 4 of the 8 factors compared between the two stocks.

How does IMAC compare to BrightSpring Health Services?

BrightSpring Health Services (NASDAQ:BTSGU) and IMAC (NASDAQ:IMAC) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BrightSpring Health Services
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
IMAC
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

BrightSpring Health Services has a net margin of 0.00% compared to IMAC's net margin of -75.40%. BrightSpring Health Services' return on equity of 0.00% beat IMAC's return on equity.

Company Net Margins Return on Equity Return on Assets
BrightSpring Health ServicesN/A N/A N/A
IMAC -75.40%-52.17%-34.51%

In the previous week, IMAC had 3 more articles in the media than BrightSpring Health Services. MarketBeat recorded 4 mentions for IMAC and 1 mentions for BrightSpring Health Services. BrightSpring Health Services' average media sentiment score of 1.60 beat IMAC's score of 0.05 indicating that BrightSpring Health Services is being referred to more favorably in the media.

Company Overall Sentiment
BrightSpring Health Services Very Positive
IMAC Neutral

BrightSpring Health Services has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BrightSpring Health Services$14.37BN/AN/AN/AN/A
IMAC$15.22M0.00-$10.54M-$0.27N/A

24.3% of IMAC shares are owned by institutional investors. 10.0% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

BrightSpring Health Services beats IMAC on 6 of the 9 factors compared between the two stocks.

How does IMAC compare to LifeMD?

IMAC (NASDAQ:IMAC) and LifeMD (NASDAQ:LFMDP) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, IMAC had 1 more articles in the media than LifeMD. MarketBeat recorded 4 mentions for IMAC and 3 mentions for LifeMD. LifeMD's average media sentiment score of 0.94 beat IMAC's score of 0.05 indicating that LifeMD is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IMAC
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
LifeMD
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

LifeMD has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$15.22M0.00-$10.54M-$0.27N/A
LifeMD$191.59MN/AN/AN/AN/A

24.3% of IMAC shares are held by institutional investors. 10.0% of IMAC shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

LifeMD has a net margin of 0.00% compared to IMAC's net margin of -75.40%. LifeMD's return on equity of 0.00% beat IMAC's return on equity.

Company Net Margins Return on Equity Return on Assets
IMAC-75.40% -52.17% -34.51%
LifeMD N/A N/A N/A

Summary

LifeMD beats IMAC on 5 of the 8 factors compared between the two stocks.

Get IMAC News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMAC vs. The Competition

Export
MetricIMACHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$16K$10.41B$7.36B$12.64B
Dividend YieldN/A2.60%2.51%19.61%
P/E Ratio0.0033.97274.1524.84
Price / Sales0.004.79624.7597.88
Price / CashN/A115.4276.1951.56
Price / Book0.005.0710.295.86
Net Income-$10.54M$315.68M$3.50B$380.67M
7 Day PerformanceN/A-1.26%-5.37%-4.97%
1 Month PerformanceN/A-5.60%-8.55%-6.95%
1 Year PerformanceN/A9.92%0.43%-5.99%

IMAC Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMAC
IMAC
N/A$0.00
flat		N/A-99.1%$16K$15.22MN/A106
NVOS
Novo Integrated Sciences
N/A$0.00
+28.6%		N/A-60.0%$36K$13.52MN/A115
BACK
IMAC
N/A$0.00
flat		N/A-99.1%$2K$72.05KN/A180
AONCW
American Oncology Network
N/A$0.00
flat		N/AN/A$0.00$1.34BN/A1,525
BTSGU
BrightSpring Health Services
N/A$210.07
-0.4%		N/A+95.4%$0.00$14.37BN/A23,500

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:IMAC) was last updated on 10/16/2026 by MarketBeat.com Staff.
From Our Partners
Why Some AI Stocks Already Surged Over 300 Percent
Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...
Brownstone Research | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
Undiscovered Sub-$1 Gold-Silver Royalty Stock Takes Flight
A small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...
Digest Publishing | Sponsoredtc pixel
Trump’s Plan To Cheat History
China has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...
Porter & Company | Sponsoredtc pixel
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...
Behind the Markets | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Elon says the ‘S’ word
Elon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men d...
Paradigm Press | Sponsoredtc pixel